277 related articles for article (PubMed ID: 22310059)
1. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
[TBL] [Abstract][Full Text] [Related]
3. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
Descamps A; Rousset C; Millan MJ; Spedding M; Delagrange P; Cespuglio R
Psychopharmacology (Berl); 2009 Jul; 205(1):93-106. PubMed ID: 19370342
[TBL] [Abstract][Full Text] [Related]
4. Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.
Morley-Fletcher S; Mairesse J; Soumier A; Banasr M; Fagioli F; Gabriel C; Mocaer E; Daszuta A; McEwen B; Nicoletti F; Maccari S
Psychopharmacology (Berl); 2011 Oct; 217(3):301-13. PubMed ID: 21503609
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light.
Tchekalarova J; Stoynova T; Ilieva K; Mitreva R; Atanasova M
Pharmacol Biochem Behav; 2018 Aug; 171():1-9. PubMed ID: 29807067
[TBL] [Abstract][Full Text] [Related]
6. The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms.
Perugi G; Quaranta G; Bucci N
Expert Opin Investig Drugs; 2015 May; 24(5):705-13. PubMed ID: 25727766
[TBL] [Abstract][Full Text] [Related]
7. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
8. Spike-Wave Discharges and Sleep-Wake States during Circadian Desynchronization: No Effects of Agomelatine upon Re-Entrainment.
Smyk MK; van Luijtelaar G; Huysmans H; Drinkenburg WH
Neuroscience; 2019 Jun; 408():327-338. PubMed ID: 30978380
[TBL] [Abstract][Full Text] [Related]
9. Circadian rhythms in obsessive-compulsive disorder.
Lange KW; Lange KM; Hauser J; Tucha L; Tucha O
J Neural Transm (Vienna); 2012 Oct; 119(10):1077-83. PubMed ID: 22543530
[TBL] [Abstract][Full Text] [Related]
10. Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats.
Tchekalarova J; Nenchovska Z; Atanasova D; Atanasova M; Kortenska L; Stefanova M; Alova L; Lazarov N
Behav Brain Res; 2016 Apr; 302():11-28. PubMed ID: 26779670
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Pandi-Perumal SR; Moscovitch A; Srinivasan V; Spence DW; Cardinali DP; Brown GM
Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
Vimala PV; Bhutada PS; Patel FR
Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
[TBL] [Abstract][Full Text] [Related]
13. Agomelatine in depressive disorders: its novel mechanisms of action.
Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
[TBL] [Abstract][Full Text] [Related]
14. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
Quera-Salva MA; Lemoine P; Guilleminault C
Hum Psychopharmacol; 2010 Apr; 25(3):222-9. PubMed ID: 20373473
[TBL] [Abstract][Full Text] [Related]
15. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.
Chenaf C; Chapuy E; Libert F; Marchand F; Courteix C; Bertrand M; Gabriel C; Mocaër E; Eschalier A; Authier N
Pain; 2017 Jan; 158(1):149-160. PubMed ID: 27984527
[TBL] [Abstract][Full Text] [Related]
17. Circadian rhythms, melatonin and depression.
Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
[TBL] [Abstract][Full Text] [Related]
18. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats.
Dagyte G; Trentani A; Postema F; Luiten PG; Den Boer JA; Gabriel C; Mocaër E; Meerlo P; Van der Zee EA
CNS Neurosci Ther; 2010 Aug; 16(4):195-207. PubMed ID: 20236141
[TBL] [Abstract][Full Text] [Related]
19. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
